Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
Customer Center
Customer Center
Case Studies Clients Testimonials Downloads Partnerships Intellectual Property Protection Newsletters
HomeClient CenterMedicilon Support
IND 100 Publications
Dec 09,2024
Medicilon Supports Partner Luye Pharma's LY09607 Clinical Trial Approval
Medicilon is proud to have supported Luye Pharmaceutical Co., Ltd. ("Luye Pharma") in securing clinical trial approval for LY09607, a new drug aimed at improving post-operative pain management.
See More
Medicilon Supports Partner Luye Pharma's LY09607 Clinical Trial Approval
Dec 09,2024
Medicilon Supports Jemincare's JMX-2002 Liposome Injection Clinical Trial Approval
Medicilon has been instrumental in advancing JMX-2002's development, providing comprehensive preclinical support through its specialized liposome drug development platform. This platform covers lipid synthesis, liposome preparation, formulation screening, safety evaluation, pharmacokinetics, and regulatory support, helping to optimize the drug's efficacy and safety profile.
See More
Medicilon Supports Jemincare's JMX-2002 Liposome Injection Clinical Trial Approval
Dec 03,2024
Medicilon Supports Partner Jemincare in Securing Clinical Approval for JM045 Sustained-Release Microspheres
Recently, JM045 sustained-release microspheres, independently developed by the Institute of Innovative Pharmaceuticals under Jemincare Pharmaceutical Group, received clinical trial approval. Medicilon provided pharmacokinetic studies and GLP-compliant safety evaluations for this development.
See More
Medicilon Supports Partner Jemincare in Securing Clinical Approval for JM045 Sustained-Release Microspheres
Nov 27,2024
Medicilon Partners with Hengrui Pharmaceuticals to Secure Clinical Approval for siRNA Drug HRS-9563
​HRS-9563, an innovative siRNA Class I drug developed by Shengdi Pharmaceuticals Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd., has received clinical trial approval.
See More
Medicilon Partners with Hengrui Pharmaceuticals to Secure Clinical Approval for siRNA Drug HRS-9563
Oct 08,2024
Medicilon assists its partner Yayo Biotech in obtaining FDA approval for the IND application of the "YY2201 Tablets," a Class 1 new drug for advanced tumor
On September 14, Yayo Biotech received an FDA IND clinical approval (IND173030) for its independently developed Class 1 innovative drug, ATR kinase inhibitor YY2201 tablets. Medicilon, as a partner of Yayo Biotech, provided comprehensive R&D services for the development of YY2201 tablets.
See More
Medicilon assists its partner Yayo Biotech in obtaining FDA approval for the IND application of the "YY2201 Tablets," a Class 1 new drug for advanced tumor
Sep 18,2024
Medicilon congratulates Genfleet Therapeutics on the approval and launch of their KRAS G12C inhibitor, Fuzerelisib.
Recently, Genfleet Therapeutics launched its KRAS G12C inhibitor, Dabote® (Fuzerelisib Tablets, GFH925/IBI351). Shanghai Medicilon Inc. (Medicilon) leveraged its well-established pharmacokinetics research platform to provide early-stage animal pharmacokinetic services for Fuzerelisib.
See More
Medicilon congratulates Genfleet Therapeutics on the approval and launch of their KRAS G12C inhibitor, Fuzerelisib.
Sep 18,2024
Value repeatedly verified! Medicilon congratulates its partner, EpimAb Biotherapeutics, on the overseas authorization of their BCMA×CD3 bispecific antibody EMB-06
On September 4th, EpimAb Biotherapeutics (EpimAb) announced that it has reached a licensing agreement with Vignette Bio, Inc. (Vignette Bio) regarding EpimAb's BCMA-targeted T-cell engager (TCE) molecule, EMB-06. As a partner of EpimAb, Shanghai Medicilon Inc. (Medicilon) congratulates EpimAb on the licensing of its BCMA×CD3 bispecific antibody EMB-06 for international markets.
See More
Value repeatedly verified! Medicilon congratulates its partner, EpimAb Biotherapeutics, on the overseas authorization of their BCMA×CD3 bispecific antibody EMB-06
Sep 10,2024
Medicilon supports its partner Jingye Medicine & Chemical Co in obtaining approval for the market launch of its gadopentetate chemical raw material
Recently, Suzhou Jingye Medicine & Chemical Co., Ltd. (Jingye) successfully obtained the "Approval Notice for the Market Launch of Chemical Raw Materials" (Notice No. 2024YS00864) issued by the National Medical Products Administration (NMPA) for its gadopentetate chemical raw material.
See More
Medicilon supports its partner Jingye Medicine & Chemical Co in obtaining approval for the market launch of its gadopentetate chemical raw material
Jun 19,2024
Medicilon helps Keye Life's new drug targeting RNA helicase obtain dual approval in China and the United States
Medicilon provided efficacy studies and safety evaluation services that comply with both Chinese GLP and U.S. GLP standards for KY1, facilitating its successful dual IND approval in both China and the United States.
See More
Medicilon helps Keye Life's new drug targeting RNA helicase obtain dual approval in China and the United States
Jun 14,2024
Medicilon assists Insilico Medicine in obtaining approval for MAT2A inhibitor in both China and the United States
Recently, ISM3412, a class 1 new drug developed by InSilico Medicine Cayman TopCo (Insilico Medicine), received implied approval for clinical trials in China. As a strategic partner of Insilico Medicine, Medicilon provided preclinical research services for ISM3412, including pharmacokinetics and safety evaluation tests​.
See More
Medicilon assists Insilico Medicine in obtaining approval for MAT2A inhibitor in both China and the United States
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->